There are currently 67 active clinical trials seeking participants for Ulcerative Colitis research studies. The states with the highest number of trials for Ulcerative Colitis participants are Florida, California, Texas and New York.
Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease
NCT04827368
Recruiting
Inflammatory Bowel Disease (IBD) are chronic diseases of the gut comprising Crohn's Disease (CD) and Ulcerative Colitis (UC). The symptoms of IBD consist of diarrhea, abdominal discomfort, weight loss, fatigue and rectal bleeding. However, symptoms and treatment vary between patients. Early management of IBD can lead to better response rates and decrease the risk of irreversible bowel damage and future disease complications such as surgeries. Current clinical tools for diagnosis and or assessing... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/06/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: IBD, Crohn Disease, Ulcerative Colitis
Register for Updates
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)
NCT04543994
Recruiting
The purpose of this study is to determine the safety and efficacy of using remestemcel-L, an ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product (MSCs) delivered by targeted endoscopic delivery to treat people for medically refractory ulcerative colitis. This study will enroll adult patients with medically refractory ulcerative colitis who are planning to switch biologic therapy or undergo colectomy as the next stage in their treatment plan.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/04/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Ulcerative Colitis
Register for Updates
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606
Recruiting
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits.
Gender:
ALL
Ages:
Between 2 years and 19 years
Trial Updated:
03/31/2025
Locations: UCSF Medical Center at Mission Bay, San Francisco, California +52 locations
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Register for Updates
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
03/31/2025
Locations: Om Research, Lancaster, California +36 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Register for Updates
Immune Regulation in Ulcerative Colitis or Crohn s Disease
NCT00001184
Recruiting
This study will investigate in patients with Crohn s disease and ulcerative colitis how the body s immune system controls inflammation in the gastrointestinal tract (stomach and intestines)-specifically, how lymphocytes (a type of white blood cell) function in inflammatory responses. This protocol does not involve any experimental treatments. Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible fo... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
03/28/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Inflammatory Bowel Disease, Ulcerative Colitis, Chrohn's Disease
Register for Updates
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059
Recruiting
The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the M... Read More
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
03/26/2025
Locations: Digestive Health Specialists ( Site 0135), Dothan, Alabama +400 locations
Conditions: Ulcerative Colitis
Register for Updates
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934
Recruiting
The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo. The primary objective of this study is to assess the efficacy of GS-1427, compared with placebo control, in achieving clinical response at Week 12.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/25/2025
Locations: Onyx Clinical Research (Clinic Location), Peoria, Arizona +128 locations
Conditions: Ulcerative Colitis
Register for Updates
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043
Recruiting
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: AnaptysBio Investigational Site 10-115, Phoenix, Arizona +99 locations
Conditions: Ulcerative Colitis
Register for Updates
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT03816345
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +51 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult participants with moderate to severe UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed. Lutikizumab is an investigational product being developed for the treatment of m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Gastro SB /ID# 258331, Chula Vista, California +183 locations
Conditions: Ulcerative Colitis
Register for Updates
R-3750 in Patients with Mild to Moderate Ulcerative Colitis
NCT05666960
Recruiting
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis. Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/19/2025
Locations: AP Medical Research LLC, Miami, Florida +2 locations
Conditions: Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic, Ulcerative Colitis
Register for Updates
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
NCT06636656
Recruiting
Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis. This study has 2 parts. In Part A, participants get BI 3032950 as an infusion into a vein every 4 weeks. After 12 weeks, doctors check whether the signs and symptoms of ulcerative colitis have improv... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/19/2025
Locations: Future Innovative Treatments, Colorado Springs, Colorado +47 locations
Conditions: Ulcerative Colitis
Register for Updates